Loading...
•
Jun 30, 2022
Nuwellis Q2 2022 Earnings Report
Reported a 15% sequential increase in revenue and a decrease in operating expenses.
Key Takeaways
Nuwellis, Inc. reported a total revenue of $2.2 million for Q2 2022, representing a 15% increase compared to the previous quarter. The company's net loss was $4.3 million, and cash and cash equivalents totaled $15.3 million as of June 30, 2022.
Total revenue for Q2 2022 was $2.2 million, up 15% sequentially.
First patient enrolled in REVERSE-HF clinical trial.
Operating expenses decreased 14% compared to Q2 2021.
Gross margin was 48.0%, impacted by lower fixed overhead absorption and a non-cash inventory write-off.
Forward Guidance
Nuwellis anticipates continued growth and strategic advancements for the remainder of 2022 and into 2023, focusing on making the Aquadex System the standard of care.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...